Study population characteristics
| Descriptive | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|---|
| Sex, n (%) | ||||||
| Female | 24 676 (52.92) | 25 352 (52.77) | 25 937 (52.61) | 26 522 (52.61) | 27 134 (52.75) | 27 739 (52.75) |
| Male | 21 957 (47.08) | 22 694 (47.23) | 23 363 (47.39) | 23 892 (47.39) | 24 307 (47.25) | 24 843 (47.25) |
| Age group, n (%) | ||||||
| 45–49 | 14 804 (31.75) | 14 682 (30.56) | 14 386 (29.18) | 14 247 (28.26) | 12 877 (26.98) | 13 718 (26.09) |
| 50–54 | 13 661 (29.29) | 14 059 (29.26) | 14 523 (29.47) | 14 639 (29.04) | 14 729 (28.63) | 14 706 (27.97) |
| 55–59 | 10 381 (22.26) | 11 090 (23.08) | 11 571 (23.47) | 12 227 (24.25) | 12 857 (24.99) | 13 532 (25.74) |
| 60–64 | 7787 (16.70) | 8215 (17.10) | 8820 (17.89) | 9301 (18.45) | 9978 (19.40) | 10 626 (20.21) |
| Multimorbidity (≥2 LTCs) | 21 775 (46.69) | 22 905 (47.67) | 24 158 (49.00) | 25 157 (49.90) | 26 263 (51.05) | 27 140 (51.61) |
| Polypharmacy (≥4 repeat medicines) | 12 651 (27.13) | 13 078 (27.22) | 13 547 (27.48) | 13 912 (27.60) | 14 201 (27.61) | 14 588 (27.74) |
| Deprivation quintilea | ||||||
| 1 (least deprived) | 10 035 (21.61) | 10 337 (21.61) | 10 620 (21.61) | 10 766 (21.41) | 10 805 (21.10) | 10 980 (20.97) |
| 2 | 9607 (20.68) | 9938 (20.77) | 10 441 (21.26) | 10 349 (20.61) | 10 943 (21.37) | 11 112 (21.22) |
| 3 | 9445 (20.34) | 9666 (20.20) | 9688 (19.73) | 10 220 (20.36) | 10 139 (19.80) | 10 278 (19.63) |
| 4 | 8922 (19.21) | 9188 (19.21) | 9547 (19.44) | 9715 (19.35) | 10 074 (19.67) | 10 459 (19.98) |
| 5 (most deprived) | 8436 (18.16) | 8712 (18.21) | 8810 (17.94) | 9153 (18.23) | 9255 (18.07) | 9529 (18.20) |
| Total PIP prevalence | 9324 (19.99) | 9644 (20.07) | 9752 (19.78) | 9716 (19.27) | 9430 (18.33) | 9582 (18.22) |
↵a There was missing data (0.4%) for the deprivation variable.